In a recently reported single-center phase 2 trial evaluating durvalumab, an anti-PD-L1 drug, and tremelimumab, an anti-CTLA-4 drug, in advanced or metastatic soft tissue and bone sarcomas, 20% (1/5) of patients with UPS showed an objective response12. Here, CTLA4 is linked to undifferentiated pleomorphic sarcoma.